Teva Pharmaceuticals Released New Tardive Dyskinesia Data
The company presented findings on provider treatment preferences and symptom burdens at the Psych Congress in New Orleans.
Updated on Sept. 18, 2026 in Alzheimer’s
Live Poll
Should medical treatments for movement disorders prioritize immediate symptom reduction over long-term risk management?
Teva Pharmaceuticals has unveiled new data from a discrete choice experiment involving 489 healthcare providers evaluating VMAT2 inhibitors for tardive dyskinesia. A separate 24-month interim analysis of the IMPACT-TD Registry further underscored the persistent impact of the condition on untreated patients.
Why it matters
Understanding how providers weigh risks like somnolence against symptom improvement is critical to optimizing care for those with tardive dyskinesia. The findings highlight the necessity of active management, as most untreated patients in the study reported stable or worsening symptoms over time.
In the provider survey, somnolence risk held a 26.8% to 36.2% decision-making weight, while symptom improvement accounted for 24.4% to 29.5%. Separately, 60% to 74% of untreated registry participants experienced moderate-to-severe TD impact.
The players
Teva Pharmaceuticals
Headquartered in Parsippany, N.J., this global pharmaceutical company focuses on generic medicines and specialty therapeutics.
The details
The experiment identified AUSTEDO as having the highest predicted choice probability among healthcare providers when balancing treatment attributes. Meanwhile, the registry data tracked individuals with tardive dyskinesia to evaluate how the condition manifests when VMAT2 inhibitors are not administered.
Timeline
September 15-19, 2026: Data presented at the Psych Congress in New Orleans.
September 18, 2026: Teva Pharmaceuticals announced the study results.
The Big Picture
This study updates the observational framework established by the IMPACT-TD Registry to document the longitudinal progression of involuntary movements. It bridges the gap between clinical trial efficacy and real-world provider decision-making regarding VMAT2 inhibitor use.
These findings help patients discuss specific treatment priorities, such as managing somnolence risks versus pursuing symptom control, with their clinicians. The registry data serves as a reminder for patients to monitor symptoms closely, as untreated tardive dyskinesia often fails to improve on its own.
The takeaway
Clinicians and patients often prioritize a balance of symptom relief and tolerability when selecting movement disorder therapies. Managing these conditions proactively is important because symptoms frequently remain stagnant or deteriorate without pharmacological intervention.
Further reading
For more information on the progression and management of neurodegenerative movement disorders, visit the Alzheimer’s section.
Live Poll
Should medical treatments for movement disorders prioritize immediate symptom reduction over long-term risk management?
